Immunoglobulin A, an Active Liaison for Host-Microbiota Homeostasis

Abokor, Ahmed A.; McDaniel, Grant H.; Golonka, Rachel M.; Campbell, Connor; Brahmandam, Sreya; Yeoh, Beng San; Joe, Bina; Saha, Piu

doi:10.3390/microorganisms9102117

Cited by 28 publications

(17 citation statements)

References 282 publications

(365 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We also investigated B-cell levels in the spleen and bone marrow because circulating IgA is primarily secreted by mature plasma cells in the bone marrow. 4,18 The % CD45RA + total B-cell population in circulation and Peyer patches were significantly lower in SHR compared to WKY rats (Figure 4A and 4B). In addition, the % CD45RA + CD127 + immature B-cell subset in SHR was substantially reduced in circulation, Peyer patches, and spleen but not in bone marrow (Figure 4C and 4D, Figure S6A and S7A), implicating that SHR has no defect in B cell development in the bone marrow.…”

Section: Shr Have Diminished B Cells In Circulation and Peyer Patchesmentioning

confidence: 94%

Selective IgA Deficiency in Spontaneously Hypertensive Rats With Gut Dysbiosis

et al. 2022

Self Cite

View full text Add to dashboard Cite

Background: The spontaneously hypertensive rat (SHR) is extensively used to study hypertension. Gut microbiota dysbiosis is a notable feature in SHR for reasons unknown. Immunoglobulin A (IgA) is a major host factor required for gut microbiota homeostasis. We hypothesized that inadequate IgA contributes to gut microbiota dysbiosis in SHR. methods: IgA was measured in feces, cecum, serum, liver, gut-associated lymphoid tissue, and milk from SHR and Wistar Kyoto rats. IgA regulatory factors like IgM, IgG, and pIgR (polymeric immunoglobulin receptor) were analyzed. IgA and IgG antibodies and blood pressure (BP) were measured before and after administrating a bacterial antigen (ie, flagellin). Results: Compared with Wistar Kyoto rats, SHR displayed remarkably near-deficient IgA levels accompanied by compensatory increases in serum IgM and IgG and gut-liver pIgR expression. Inadequate milk IgA in SHR emphasized this immune defect stemmed from the neonatal stage. Reduced IgA + B cells in circulation and Peyer patches indicated a possible reason for the lower IgA in SHR. Noteworthy, a genetic insufficiency was unlikely because administering flagellin to SHR induced anti-flagellin IgA antibodies. This immune response surprisingly accelerated hypertension development in SHR, suggesting IgA quiescence may help maintain lower BP. Conclusions: This study is the first to reveal IgA deficiency in SHR as one host factor associated with gut microbiota dysbiosis and invigorates future research to determine the pathophysiological role of IgA in hypertension.

show abstract

Section: Shr Have Diminished B Cells In Circulation and Peyer Patchesmentioning

confidence: 94%

Selective IgA Deficiency in Spontaneously Hypertensive Rats With Gut Dysbiosis

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…Furthermore, BAFF favors the survival of high-affinity B-cell clones and activates class switch recombination of immunoglobulins [ 34 , 35 ]. It has been demonstrated that overexpression of BAFF in mice induces a significant expansion of activated B-cells and marginal zone B-cells, as well as hypergammaglobulinemia and autoantibody production [ 36 , 37 ]. On the other hand, BAFF co-stimulates T-cell activation and proliferation and promotes its differentiation into effector cells [ 38 ].…”

Section: Baff Biology and Role In Other Diseasesmentioning

confidence: 99%

Role of B-Cell Activating Factor (BAFF) in Inflammatory Bowel Disease

et al. 2021

View full text Add to dashboard Cite

As early commencement of inflammatory bowel disease (IBD) treatment has been shown to substantially improve outcomes, it is of utmost importance to make a timely diagnosis of this disease. Despite undisputed sensitivity of fecal calprotectin, the most widely accepted IBD biomarker, in discriminating between irritable bowel syndrome (IBS) and IBD, as well as recognized role in monitoring disease activity and response to therapy, perhaps the biggest setback of calprotectin use in IBD is lack of specificity. Therefore, an additional biomarker in IBD is warranted. B-cell activating factor (BAFF), a member of the tumor necrosis factor (TNF) superfamily, recently emerged as a viable candidate for this role. So far, overproduction of BAFF has been observed in various autoimmune diseases, most notably in systemic lupus erythematosus, where BAFF-inhibitor belimumab was approved for treatment. As BAFF levels were also shown to correlate with indices of IBD, in this review we aimed to summarize the current evidence with respect to the role of BAFF in diagnosis and assessing the activity of IBD, as well as putative therapeutic implications that may arise from exploring of this relation.

show abstract

“…Activation of B cells leads to the secretion of IgA, which plays an important role in the regulation of the gut microbiome. Immunoglobulin A, on the one hand, is involved in the binding and elimination of pathogenic bacteria, and on the other hand, it facilitates the translocation of commensals into Peyer's patches, activating the mechanisms of immunological tolerance and thereby stimulating the growth of intestinal symbionts[ 30 , 31 ].…”

Section: Gut Microbiota and Intestinal Barriermentioning

confidence: 99%

Microbiota of the gastrointestinal tract: Friend or foe?

Сеньчукова¹

2023

World J Gastroenterol

View full text Add to dashboard Cite

The gut microbiota is currently considered an external organ of the human body that provides important mechanisms of metabolic regulation and protection. The gut microbiota encodes over 3 million genes, which is approximately 150 times more than the total number of genes present in the human genome. Changes in the qualitative and quantitative composition of the microbiome lead to disruption in the synthesis of key bacterial metabolites, changes in intestinal barrier function, and inflammation and can cause the development of a wide variety of diseases, such as diabetes, obesity, gastrointestinal disorders, cardiovascular issues, neurological disorders and oncological concerns. In this review, I consider issues related to the role of the microbiome in the regulation of intestinal barrier function, its influence on physiological and pathological processes occurring in the body, and potential new therapeutic strategies aimed at restoring the gut microbiome. Herewith, it is important to understand that the gut microbiota and human body should be considered as a single biological system, where change of one element will inevitably affect its other components. Thus, the study of the impact of the intestinal microbiota on health should be considered only taking into account numerous factors, the role of which has not yet been fully elucidated.

show abstract

Immunoglobulin A, an Active Liaison for Host-Microbiota Homeostasis

Cited by 28 publications

References 282 publications

Selective IgA Deficiency in Spontaneously Hypertensive Rats With Gut Dysbiosis

Selective IgA Deficiency in Spontaneously Hypertensive Rats With Gut Dysbiosis

Role of B-Cell Activating Factor (BAFF) in Inflammatory Bowel Disease

Microbiota of the gastrointestinal tract: Friend or foe?

Contact Info

Product

Resources

About